BioStem Technologies AI Stock Analysis
Want to see BSEM full AI Analyst Report?
BioStem Technologies (BSEM) AI Stock Analysis
BioStem Technologies
(NASDAQ:BSEM)
The score is held down primarily by weak and volatile financial performance (TTM losses and cash burn) and bearish technicals (price well below key moving averages with negative MACD). Valuation provides limited support due to a negative P/E, while the earnings call adds only partial offset on improved revenue guidance and planned cost/margin initiatives amid significant near-term liquidity and execution risk.
BioStem Technologies (BSEM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $17.93M
- Dividend Yield
- ―
- Average Volume (3M)
- 187.93K
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 1.88
- Revenue Growth
- -86.50%
- EPS Growth
- -291.62%
- Country
- US
- Employees
- 73
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
BioStem Technologies Business Overview & Revenue Model
Company Description
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used...
BioStem Technologies Earnings Call Summary
The call presented meaningful operational and commercial progress, including hospital revenue growth, stronger multi-product adoption, expanded GPO access, completed systems integration, raised 2026 revenue guidance and planned cost and manufacturing initiatives. However, these positives were balanced by declining total revenue, lower gross margins, higher operating expenses, a widening net and adjusted EBITDA loss, reduced cash, increased operating cash use and an outstanding BioTissue payment. The overall tone was cautiously optimistic about the 2027 plan but acknowledged substantial near-term financial and liquidity challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
BioStem continues to expect sequential growth in the fourth quarter, with minimal contributions from the physician office channel, and raised its full year 2026 revenue guidance to $28 million to $29 million from the previous range of $26 million to $29 million; in 2027, operating expenses are expected to decline substantially and the adjusted EBITDA loss to narrow across 2027, while the cost reduction plan is expected to lower annualized cash operating expenses by approximately $10 million to $12 million, with the full benefit beginning in the first quarter of 2027. The company expects to complete the Neox and Clarix technology transfer and begin in-house production in the first half of 2027, subject to process validation and applicable regulatory requirements; margins are expected to remain in the 50s until then, and management said it feels it can get into the 70s, with a 10 to 15-point improvement in gross margin over time.
BioStem Technologies Financial Statement Overview
Summary
Fundamentals are pressured by a sharp swing to deep losses and cash burn in TTM, with negative profitability and negative operating/free cash flow signaling rising funding needs. The balance sheet is comparatively better (manageable leverage and positive equity), but the deterioration from strong 2024 results to weak TTM raises durability and liquidity concerns.
Income Statement
22NegativeBalance Sheet
56NeutralCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -63.14M | 47.48M | 301.83M | 16.69M | 6.88M | 4.34M |
| Gross Profit | -73.61M | 44.22M | 288.08M | 15.42M | 5.99M | 2.87M |
| EBITDA | -34.04M | -308.13K | 31.49M | -7.55M | -6.54M | -602.11K |
| Net Income | -40.43M | -6.58M | 31.88M | -8.48M | -7.19M | -1.45M |
Balance Sheet | ||||||
| Total Assets | 43.58M | 50.03M | 140.38M | 14.56M | 3.47M | 2.67M |
| Cash, Cash Equivalents and Short-Term Investments | 971.14K | 29.55M | 22.83M | 239.41K | 772.14K | 340.33K |
| Total Debt | 1.17M | 3.33M | 4.39M | 4.72M | 5.09M | 4.83M |
| Total Liabilities | 25.25M | 10.89M | 99.50M | 15.90M | 7.42M | 8.47M |
| Stockholders Equity | 18.33M | 39.14M | 40.88M | -1.34M | -4.08M | -5.96M |
Cash Flow | ||||||
| Free Cash Flow | -12.85M | 6.59M | 24.05M | -3.71M | -165.91K | -152.29K |
| Operating Cash Flow | -12.36M | 9.94M | 24.48M | -3.50M | 303.57K | -109.44K |
| Investing Cash Flow | -15.68M | -2.10M | -1.68M | -210.33K | -469.48K | -7,848 |
| Financing Cash Flow | 1.85M | -1.12M | -206.78K | 3.18M | 597.71K | 357.42K |
BioStem Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSEM, the sentiment is Negative. The current price of 0.94 is below the 20-day moving average (MA) of 1.27, below the 50-day MA of 2.47, and below the 200-day MA of 3.91, indicating a bearish trend. The MACD of -0.36 indicates Negative momentum. The RSI at 31.65 is Neutral, neither overbought nor oversold. The STOCH value of 12.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BSEM.
BioStem Technologies Peers Comparison
Overall Rating
NCEL48Neutral
CELU47Neutral
JSPR46Neutral
LGVN45Neutral
BSEM44Neutral
PLUR27Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $14.43M | 8.12 | 21.75% | ― | ― | ― | |
| 47Neutral | $18.53M | -0.32 | 142.25% | ― | -58.14% | 47.25% | |
| 46Neutral | $11.47M | -0.37 | 39.72% | ― | ― | 16.44% | |
| 45Neutral | $6.71M | -0.26 | -243.26% | ― | -18.93% | 39.19% | |
| 44Neutral | $17.93M | -0.40 | -138.28% | ― | -86.50% | -291.62% | |
| 27Underperform | $14.09M | -0.36 | 147.42% | ― | 10.03% | 13.85% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BSEM | BioStem Technologies | 0.94 | -2.81 | -75.07% | |
| PLUR | Pluri Inc. | 0.98 | -2.58 | -72.47% | |
| CELU | Celularity Inc. | 0.57 | -1.12 | -66.21% | |
| JSPR | Jasper Therapeutics, Inc. | 10.34 | -45.16 | -81.37% | |
| NCEL | Newcelx Ltd. | 2.68 | -0.63 | -19.03% | |
| LGVN | Longeveron Inc. | 2.11 | -4.04 | -65.67% |
BioStem Technologies Corporate Events
BioStem Technologies Completes $3 Million Private Placement Financing
NegativeOn September 29–30, 2026, BioStem Technologies raised approximately $3 million in a private placement, selling 735,296 shares of common stock at $4.08 per share along with Series A and Series B warrants for an equal number of shares, each carrying a...
BioStem Secures $40 Million Equity Financing Facility
PositiveOn September 18, 2026, BioStem Technologies entered into a $40 million committed equity facility with Roth Principal Investments, giving the company the right, but not the obligation, to sell up to 12,050,000 registered common shares over a 36‑month...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
